Judges Scientific plc (AIM:JDG)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 315.04M |
| Revenue (ttm) | 145.80M |
| Net Income (ttm) | 5.50M |
| Shares Out | 6.66M |
| EPS (ttm) | 0.81 |
| PE Ratio | 58.11 |
| Forward PE | 23.39 |
| Dividend | 1.15 (2.43%) |
| Ex-Dividend Date | Jun 11, 2026 |
| Volume | 9,845 |
| Average Volume | 11,453 |
| Open | 4,720.00 |
| Previous Close | 4,730.00 |
| Day's Range | 4,600.00 - 4,800.00 |
| 52-Week Range | 3,600.00 - 9,120.00 |
| Beta | 0.71 |
| RSI | 68.04 |
| Earnings Date | Sep 23, 2026 |
About Judges Scientific
Judges Scientific plc designs, manufactures, and sells scientific instruments and services in the United Kingdom and internationally. It operates through two segments: Materials Sciences and Vacuum. The company offers engineering teaching and research equipment for universities, colleges, schools, and research centres; and research and development systems for food, beverages, dairy, edible oils, ingredients and pharmaceuticals industries. It also provides cutting edge LED illumination systems for researchers and clinicians; tensile testing, mot... [Read more]
Financial Performance
In 2025, Judges Scientific's revenue was 145.80 million, an increase of 9.13% compared to the previous year's 133.60 million. Earnings were 5.50 million, a decrease of -47.12%.
Financial StatementsNews
Judges Scientific PLC (JSCIF) Full Year 2025 Earnings Call Highlights: Navigating Challenges ...
Judges Scientific PLC (JSCIF) Full Year 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth
Judges Scientific Earnings Call Transcript: H2 2025
FY2025 saw revenue growth but flat profits due to U.S. funding cuts and weak order intake, partially offset by strong performance in industrial and Asian markets. Cash generation remained robust, dividend increased 10%, and guidance for 2026 EPS is 200–250p, with long-term fundamentals intact.
Judges Scientific Earnings Call Transcript: H1 2025
Revenue and profit grew strongly year-over-year, driven by Geotech and China, but U.S. funding cuts and weak order intake tempered results. Cash generation remains robust, leverage is down, and dividends continue to rise. Management expects to meet revised guidance and remains confident in long-term growth drivers.
Judges Scientific Earnings Call Transcript: H2 2024
2024 saw a 2% revenue decline and a 24% drop in adjusted EPS due to weak order intake, especially from China and the absence of a major coring contract. Despite this, three acquisitions were completed, cash conversion was strong, and the dividend was raised 10%.
Judges Scientific Earnings Call Transcript: H1 2024
H1 2024 saw a 1% revenue decline and 13% drop in adjusted operating profit amid subdued order intake, especially in China, and absence of a major contract. Despite short-term headwinds, the group completed three acquisitions, raised its dividend 10%, and extended banking facilities.